Is the biotechnology revolution a myth?

Comprehensive Medicinal Chemistry II

Volumn 1, Issue , 2006, Pages 591-613

  Hopkins, M M ^a   Kraft, A ^b   Martin, P A ^b   Nightingale, P ^a   Mahdi, S ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45049088844     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (105)

1. Kevles, D.; Hood, L.;. The Code of Codes: Scientific and Social Issues in the Human Genome Project, Harvard University Press: Cambridge, MA, 1992.
2. Organization for Economic Co-operation and Development. Biotechnology and Medical Innovation: Socioeconomic Assessment of the Technology, the Potential and the Products'; Paris, 1997.
3. Organization for Economic Co-operation and Development. Economic Aspects of Biotechnologies Related to Human Health Part II: Biotechnology, Medical Innovation and the Economy: The Key Relationships': Paris, 1998.
4. Bell, J. I. Nature 2003, 421, 414-416.
5. Bioscience, Innovation and Growth Team (BIGT). Bioseienee 2015', Department of Trade and Industry: London, 2003.
6. European Commission. Life Sciences and Biotechnology: A Strategy for the European Community, Brussels, 2002.
7. Organization for Economic Co-operation and Development. Committee for Scientific and Technological Policy at Ministerial Level ''Science, Technology and Innovation for the 21st Century'', Final Communique Meeting, 29-30 Jan, Paris, 2004.
8. Bell, J. Br. Med. J. 1998, 316, 618-620.
9. Collins, F S.; Patrinos, A.; Jordan, E.; Chakravarti, A.; Gesteland, R.; Walters, L.; the members of the DOE and NIH planning groups. Science 1998, 282, 682-689.
10. Lenaghan, J. Brave New NHS? Institute for Public Policy Research: London, 1998.
11. Lindpaintner, K. Br. J. Clin. Pharmacol. 2002, 54, 221-230.
12. Department of Health. Our Inheritance, Our Future: Realizing the Potential of Genetics in the NHS; HMSO: London, 2003.
13. Department of Trade and Industry. Biotechnology Clusters; HMSO: London, 1999.
14. Enriquez, J.; Goldberg, R. A. Harvard Bus. Rev. 2000, 78, 94-104.
15. Tollman, P; Guy, P.; Altshuler, J.; Flanagan, A.; Steiner, M. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry; The Boston Consulting Group: Boston, MA, 2001.
16. House of Commons Science and Technology Committee. Human Genetics: The Science and its Consequences; HMSO: London, 1995.
17. Department of Trade and Industry. Science and Innovation Strategy; London, 2001.
18. Dohse, D. Res. Policy 2000, 20, 1111-1133.
19. Giesecke, S. Res. Policy 2000, 29, 205-223.
20. Reiss, T; Hinze, S.; Dominguez Lacasa, I.; Mangematin, V; Enzing, C.; van der Giessen, A.; Kern, S.; Senker, J.; Calvert, J.; Nesta, L. et al. Efficiency of Innovation Policies in High Technology Sectors in Europe (EPOHITE); Office for Official Publications of the European Communities: Luxembourg, 2003.
21. Ernst and Young. Refocus: The European Perspective Global Biotechnology Report; London, 2004.
22. Gassmann, O.; Reepmeyer, G.; von Zedtwitz, M. Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry; Springer-Verlag: London, 2004.
23. Nightingale, P; Martin, M. Trends Biotechnol 2004, 22, 564-569.
24. Office of Technology Assessment. Biotechnology in a Global Economy, OTA-BA-494; US Government Printing Office: Washington, DC, 1991.
25. Sharp, M. The New Biotechnology: European Governments in search of a strategy Industrial Adjustment and Policy: VI, Sussex European Papers No. 15; Science Policy Research Unit, University of Sussex: Brighton, UK, 1985.
26. Bud, R. The Uses of Life: A History of Biotechnology; Cambridge University Press: Cambridge, UK, 1993.
27. Teich, M.; Porter, R.;. The Industrial Revolution in National Context: Europe and the USA; Cambridge University Press: Cambridge, UK, 1996.
28. Cannadine, D. Past Present 1984, 103, 31-72.
29. Floud, R.; McCloskey, D. Eds.;. The Economic History of Britain since 1700, Vol. 1, 1700-1860; Cambridge University Press: Cambridge, UK, 1984.
30. Schumpeter, J. A. The Theory of Economic Development: An Inquiry into Profits, Capital, Credit, Interest, and the Business firm; Harvard University Press: Cambridge, MA, 1934.
31. David, P. A. Am. Econ. Rev. 1990, 80, 355-361.
32. Rosenberg, N. Technol. Culture 1979, 20, 25-51.
33. Freeman, C. Technological Revolutions and Catching Up: Information and Communication Technologies and the Newly Industrializing Countries. In The Dynamics of Technology, Trade and Growth; Fagerberg, J., Verspagen, B., von Tunzelmann, N., Eds.; Edward Elgar: Aldershot, UK, 1993, pp 198-221.
34. von Tunzelman, G. N. Technological and Organizational Change in Industry during the Early Industrial Revolution. In TheIndustrialRevolution and British Society; O'Brien, P K., Quinault, R., Eds.; Cambridge University Press: Cambridge, UK, 1993, pp 254-282.
35. Crafts, N. F R. J. Econ. Hist. 1995, 55, 745-772.
36. Crafts, N. Econ. J. 2004, 114, 338-351.
37. Rosenberg, N.; Trajtenberg, M. J. Econ. Hist. 2001, 64, 61-99.
38. Devine, W. D., Jr. J. Econ. Hist. 1983, 43, 347-372.
39. Nightingale, P. Res. Policy 2004, 33, 1259-1284.
40. Freeman, C.; Louca, F. As Time Goes By: From the Industrial Revolution to the Information Revolution; Oxford University Press: Oxford, UK, 2002.
41. von Tunzelmann, G. N. Steam Power and British Industrialization to 1860; Clarendon Press: Oxford, UK, 1978.
42. Nightingale, P. J. Indust. Corp. Change 2000, 9, 315-359.
43. Bognor, W C. Drugs to Market; Pergamon Press: Oxford, UK, 1996.
44. Vos, R. Drugs Looking for Diseases; Kluwer Academic: Amsterdam, Netherlands, 2001.
45. Pavlou, A. K.; Reichert, J. M. Nat. Biotechnol. 2004, 22, 1513-1519.
46. Edgington, S. M. Biotechnology 1992, 10, 1529-1534.
47. Brekke, O. H.; Sandlie, I. Nat. Rev. Drug Disc. 2003, 2, 52-62.
48. Knight, P. Bio/technology 1990, 7, 105-107.
49. Nightingale, P; Mahdi, S. The Evolution of the Pharmaceutical Industry. In Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech; Mazzucato, M. Dosi, G. Eds.; Cambridge University Press: Cambridge, UK, 2005, Chapter 3.
50. Booth, B.; Zemmel, R. Nat. Rev. Drug Disc. 2004, 3, 451-456.
51. Ma, P; Zemmel, R. Nat. Rev. Drug Disc. 2002, 1, 571-572.
52. Friedrich, G. A. Nat. Biotechnol. 1996, 14, 1234-1237.
53. Shriver, Z.; Raguram, S.; Sasisekharan, R. Nat. Rev. Drug Disc. 2004, 3, 863-873.
54. Kramer, R.; Cohen, D. Nat. Rev. Drug Disc. 2004, 3, 965-972.
55. Senker, J.; Enzing, C.; Joly, P; Reiss, T. Nat. Biotechnol. 2000, 18, 605-609.
56. Rothman, H.; Kraft, A. J. Gommer. Biotechnol. 2006, 12, 86-98.
57. Powell, W W; White, D. R.; Koput, K. W; Owen-Smith, J. Am. J. Soci 2005, 110, 1132-1205.
58. Drews, J. Nat. Biotechnol. 1996, 14, 1516-1518.
59. Hopkins, A. L.; Groom, C. R. Nat. Rev. Drug Disc. 2002, 1, 727-730.
60. Stein, L. D.; Stein, L. D. Nature 2004, 431, 915-916.
61. Van Brunt, J. 2002.http://www.signalsmag.com (accessed May 2006).
62. Service, R. Science 2004, 303, 1796-1799.
63. Drews, J.; Ryser, S. Nat. Biotechnol. 1997, 15, 1318-1319.
64. Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products'; Bethesda, MD, 2004.
65. Organization for Economic Co-operation and Development. Compendium of Patent Statistics'; Paris, 2004.
66. Leheny, R. The Fruits of Genomics: Drug Pipelines Face Indigestion Until the New Biotechnology Ripens'; Lehman Brothers and McKinsey & Co: NewYork, 2001.
67. Campbell, N. Eur. Biopharma Rev. 2001, (Mar), 52-58
68. Hopkins, A. Drug Discov. Today 2004, 3, 173-175.
69. Marshall, A. Nat. Biotechnol. 1997, 15, 1249-1252.
70. McCarthy, A. New Genet. Society 2000, 19, 135-144.
71. Webster, A.; Martin, P; Lewis, G.; Smart, A. Nat. Rev. Genet. 2004, 5, 7-13.
72. Institute for Prospective Technological Studies. Pharmacogenetics and Pharmacogenomics: State-of-the-Art and Potential Socio-Economic Impacts in the EU. European Commission Joint Research Centre: Seville, Spain, 2006.
73. Hackett, J. L.; Lesko, L. J. Nat. Biotechnol. 2003, 21, 742-743.
74. Kola, I.; Landis, J. Nat. Rev. Drug Disc. 2004, 3, 711-715.
75. Van Brunt, J. 2004. Biomarkers: The Pendulum Finally Swings. www.signalsmag.com (accessed May 2006).
76. Pollack, A. Rebellious Bodies Dim the Glow of ''Natural Biotech Drugs.''. New York Times, July 30, 2002, p F5.
77. Joppi, R.; Bertele, V; Garattini, S. Br. Med. J. 2005, 331, 895-897.
78. Martin, P A.; Morrison, M. M. Realizing the Promise of Genomic Medicine'; Royal Pharmaceutical Society: London, 2006.
79. Reichert, J. M.; Rosenweig, C. J.; Faden, L. B.; Dewtiz, M. C. Nat. Biotechnol. 2005, 23, 1073-1078.
80. DiMasi, J. A. Clin. Pharmacol. Ther. 2001, 69, 297-307.
81. Bolten, B. M.; DeGregorio, T. Nat. Rev. Drug Disc. 2002, 1, 335-336.
82. Dickson, M.; Gagnon, J. P. Nat. Rev. Drug Disc. 2004, 3, 417-429.
83. Horrobin, D. F. Nat. Rev. Drug Disc. 2003, 2, 151-154.
84. Higgs, G. Drug Discov. Today 2004, 9, 727-729.
85. Horrobin, D. F. Nature 2001, 19, 1099-1100.
86. Kaitin, K. I.; DiMasi, J. A. Drug Inform. J. 2000, 34, 673-680.
87. Reichert, J. M. Nat. Rev. Drug Disc. 2003, 2, 695-702.
88. Glassman, R. H.; Sun, A. Y. Nat. Rev. Drug Disc. 2004, 3, 177-183.
89. Cantor, C. The Challenges to Technology and Informatics. In The Code of Codes: Scientific and Social Issues in the Human Genome Project'; Kevles, D., Hood, L., Eds.; Harvard University Press: Cambridge, MA, 1992, pp 98-111.
90. Gilbert, W A Vision of the Grail. In The Code of Codes: Scientific and Social Issues in the Human Genome Project'; Kevles, D., Hood, L., Eds.; Harvard University Press: Cambridge, MA, 1992, pp 83-97.
91. Hood, L. Biology and Medicine in the Twenty-First Century. In The Code of Codes: Scientific and Social Issues in the Human Genome Project'; Kevles, D., Hood, L., Eds.; Harvard University Press: Cambridge, MA, 1992, pp 136-163.
92. Department of Health. The Genetics of Common Diseases'; HMSO: London, 1995.
93. Roses, A. D. Nature 2000, 405, 857-865.
94. Royal Society. Personalized Medicines: Hopes and Realities; OML: London, 2005.
95. Cooper, R. S.; Psaty, B. M. Ann. Intern. Med. 2003, 138, 576-580.
96. Arundel, A.; Mintzes, B. The Impact of Biotechnology on Health; Merit-Innogen Working; Paper University of Edinburgh: Edinburgh, UK, 2004.
97. Arnst, C. Biotech, Finally. Business Week, June 13, 2005, pp 41-46.
98. Kneller, R. Nat. Biotechnol. 2005, 23, 529-530.
99. Dibner, M. Trends Biomed. Res. 1993, Sept. 6, 553-558
100. Mitchell, P. Nat. Biotechnol. 2005, 23, 906.
101. Sneader, W. Drug Discovery: A History'; John Wiley: Chichester, UK, 2005.
102. Bergman, G. Today's Biotech Breakthroughs Are Saving the Lives of Patients. The Financial Times, Nov 18, 2004, p 20.
103. Pisano, G. P. The Development Factory: Unlocking the Potential of Process Innovation', Harvard Business School Press: Boston, MA, 1997.
104. AstraZeneca 2001. Annual Report and Form 20-http://www2.astrazeneca.com/annualrep2001/default.asp (accessed May 2006).
105. Guice, J. Res. Policy 1999, 28, 81-98.